2026年5月27日 · 自动抓取 · 最新研究 · 1 分钟阅读

Sepsis risk associated with clonal hematopoiesis of indeterminate potential (CHIP): a secondary analysis of the ASPREE trial

Leukemia, Published online: 27 May 2026; doi:10.1038/s41375-026-02995-2Sepsis risk associated with clonal hematopoiesis of indeterminate potential (CHIP): a secondary analysis of the ASPREE trial

本文自动抓取自 Leukemia，原文链接：Sepsis risk associated with clonal hematopoiesis of indeterminate potential (CHIP): a secondary analysis of the ASPREE trial

原文发布日期：2026-05-27

Back to Blog

View All Posts »

<i>TP53</i> deficiency in AML induces resistance to T-cell engagers through an immunosuppressive secretome

Leukemia, Published online: 01 June 2026; doi:10.1038/s41375-026-02991-6TP53 deficiency in AML induces resistance to T-cell engagers through an immunosuppressive secretome

揭秘B细胞急性淋巴细胞白血病双靶点CAR-T疗法复发的细胞与分子机制

B细胞急性淋巴细胞白血病（B-ALL）是一种起源于B细胞的血液系统恶性肿瘤。近年来，同时瞄准CD19和CD22两个靶点的“双靶向”CAR-T细胞疗法（一种经过基因工程改造，能精准识别并杀灭癌细胞的免疫疗法）在治疗此类白血病中展现出巨大潜力。然而，部分患者在治疗后依然会面临疾病复发（Relapse，即肿瘤再次出现）的困境。为了找出导致复发的“元凶”，研究人员深入探究了其背后的细胞和分子机制。他们

骨髓增殖性肿瘤合并慢性髓系白血病：JAK2靶向治疗与额外突变的潜在影响

本研究深入探讨了骨髓增殖性肿瘤（Myeloproliferative Neoplasm, MPN）同时合并慢性髓系白血病（Chronic Myeloid Leukemia, CML）这一极其罕见病例背后的“克隆动态”与“治疗压力”机制。通俗来讲，就是观察患者体内不同癌细胞群（即不同“克隆”）在受到药物打击时的相互博弈和消长变化。研究发现，针对特定基因（如 JAK2）的靶向治疗以及体内其他额外基因突

Genetic and Clinical Features in TP53-Mutated Patients With Myelodysplastic Neoplasms: A Retrospective Study Based on Next-Generation Sequencing Data.

The recent fifth edition of World Health Organization and International Consensus Classification in 2022 recognized TP53-mutated myelodysplastic neoplasms (MDS) as a distinct entity requiring multi-hi

Related Posts

<i>TP53</i> deficiency in AML induces resistance to T-cell engagers through an immunosuppressive secretome

揭秘B细胞急性淋巴细胞白血病双靶点CAR-T疗法复发的细胞与分子机制

骨髓增殖性肿瘤合并慢性髓系白血病：JAK2靶向治疗与额外突变的潜在影响

Genetic and Clinical Features in TP53-Mutated Patients With Myelodysplastic Neoplasms: A Retrospective Study Based on Next-Generation Sequencing Data.